A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION
Phase of Trial: Phase III
Latest Information Update: 08 Jan 2020
Price : $35 *
At a glance
- Drugs RPh 201 (Primary)
- Indications Optic nerve disorders
- Focus Registrational; Therapeutic Use
- Acronyms NAION
- Sponsors Regenera Pharma
- 15 Dec 2019 Planned End Date changed from 1 May 2020 to 1 Dec 2020.
- 15 Dec 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 02 Aug 2018 According to a Regenera media release, the final data from this study is expected in Q4 2019.